Irvine-based Beta Bionics, which recently went public, saw two-year revenue increase more than eight-fold to $103.2 million.
IRVINE, Calif., June 19, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (BBNX), a pioneering leader in the development of advanced diabetes management solutions, announced its intention to integrate its ...
Please provide your email address to receive an email when new articles are posted on . The iLet bionic pancreas system conferred an average glucose of less than 183 mg/dL in 97% of adults with type 1 ...
Abbott Laboratories is back with another collaboration in the diabetes tech space. The Abbott Park, IL-based company announced an agreement with Beta Bionics, the developer of the iLet Bionic Pancreas ...
Advanced report intelligence delivers actionable guidance to improve outcomes for people using the iLet Bionic PancreasIRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Beta Bionics today announced ...
Beta Bionics Inc., which makes a “bionic pancreas,” has secured $60 million in a Series E funding round led by new investor Wellington Management. The funding fuels Beta Bionics’ continued ...
SAN ANTONIO, Texas (Ivanhoe Newswire) – The FDA recently approved a device for diabetics, called the “bionic pancreas,” taking much of the burden of continually entering carb intake, off the user.
Abbott Laboratories (NYSE:ABT) is one of the high profit margin stocks to buy now. On June 19, Beta Bionics Inc. (NASDAQ:BBNX) announced its plan to integrate its iLet Bionic Pancreas automated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results